Redundant studies that were irrelevant, gave no information about patients’ KRAS status, included additional mAbs, such as bevacizumab, not oxaliplatin\based chemotherapy, or included second\ and third\line treatment for mCRC were excluded
Redundant studies that were irrelevant, gave no information about patients’ KRAS status, included additional mAbs, such as bevacizumab, not oxaliplatin\based chemotherapy, or included second\ and… Read More »Redundant studies that were irrelevant, gave no information about patients’ KRAS status, included additional mAbs, such as bevacizumab, not oxaliplatin\based chemotherapy, or included second\ and third\line treatment for mCRC were excluded